Other substances

Edotecarin

A topoisomerase I inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Edotecarin is a synthetic topoisomerase I inhibitor with antineoplastic activity (NCIt).

Edotecarin on DrugBank
Edotecarin on PubChem

 

Structure image - Edotecarin

C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O

Supporting references

Link Tested on Impact factor Notes Publication date
Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment
in silico 2.08

In silico screening of ACE2 inhibitors.

 Jul/23/2020
Export (.csv)